BioInvent International AB (BINV) NPV
BioInvent International AB (BioInvent) is a Sweden-based biopharmaceutical company. The Company is engaged in the research and development of antibody-based drugs for the treatment of diseases, such as thrombosis, cancer and acute coronary artery disease. Its product range includes human antibodies, such as TB-402, TB-403, BI-204 and BI-505, as well as licenses. BioInvent is active in the co-development of intellectual property through strategic product alliances with ThromboGenics Ltd and Roche Group. It has has entered into several product partnerships with Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier. As of December 31, 2011, the Company had one wholly owned subsidiary BioInvent Finans AB, engaged in the administration of warrants issued by the Company. As of December 31, 2011, the Company’s largest shareholder was JP Morgan Bank. In May 2014, the Company sold back all its rights to product candidate ADC-1013 to its former partner Alligator Bioscience AB.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.